Benjamin F. Edwards & Company’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
$5K Buy
411
+189
+85% +$2.68K ﹤0.01% 1882
2024
Q1
$3K Buy
222
+122
+122% +$1.88K ﹤0.01% 1970
2023
Q4
$2K Hold
100
﹤0.01% 1997
2023
Q3
$1K Hold
100
﹤0.01% 1717
2023
Q2
$2K Sell
100
-200
-67% -$3.3K ﹤0.01% 1675
2023
Q1
$5K Hold
300
﹤0.01% 1547
2022
Q4
$3K Sell
300
-200
-40% -$1.86K ﹤0.01% 1682
2022
Q3
$4K Buy
500
+100
+25% +$993 ﹤0.01% 1604
2022
Q2
$3K Sell
400
-661
-62% -$6.31K ﹤0.01% 1642
2022
Q1
$13K Sell
1,061
-1,454
-58% -$30.6K ﹤0.01% 1318
2021
Q4
$86K Sell
2,515
-6
-0.2% -$235 ﹤0.01% 920
2021
Q3
$122K Sell
2,521
-10
-0.4% -$463 0.01% 803
2021
Q2
$114K Sell
2,531
-96
-4% -$4.25K 0.01% 808
2021
Q1
$127K Sell
2,627
-373
-12% -$19.4K 0.01% 784
2020
Q4
$162K Sell
3,000
-100
-3% -$4.52K 0.01% 694
2020
Q3
$114K Sell
3,100
-1,000
-24% -$37.2K 0.01% 715
2020
Q2
$127K Sell
4,100
-200
-5% -$5.54K 0.01% 676
2020
Q1
$119K Buy
4,300
+221
+5% +$6.62K 0.01% 641
2019
Q4
$119K Sell
4,079
-471
-10% -$11.2K 0.01% 745
2019
Q3
$87K Buy
4,550
+1,950
+75% +$45.7K 0.01% 775
2019
Q2
$57K Buy
+2,600
New +$57.1K ﹤0.01% 868

Other funds holding NEO

Benjamin F. Edwards & Company's NEO Position: Q2 2024 in Review

Benjamin F. Edwards & Company increased its NeoGenomics (NEO) stake by 85% in Q2 2024, buying an estimated $2.68K and bringing the position to 411 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1882.

Benjamin F. Edwards & Company first reported a position in NEO in Q2 2019 and has held it in 21 quarters since. The position peaked at $162K in Q4 2020. 259 funds tracked by Wall St. Rank hold NEO as of Q2 2024.

  • Benjamin F. Edwards & Company held 411 shares of NeoGenomics worth $5K as of Q2 2024.
  • Benjamin F. Edwards & Company bought 189 NeoGenomics shares in Q2 2024, an estimated $2.68K.
  • NeoGenomics made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #1882 holding.
  • Benjamin F. Edwards & Company first reported a position in NeoGenomics in Q2 2019 and has held it in 21 quarters since.
  • Benjamin F. Edwards & Company's NeoGenomics position peaked at $162K in Q4 2020.
  • 259 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.